Track 1:Latest Biosimilars in Asian Scenario

• Track 1-1Prospects of Biosimilars in Asian market

• Track 1-2Approved Biosimilars in Asia-Pacific Region

• Track 1-3Regulatory guidelines in the Asia-Pacific region

• Track 1-4Market stratergy, analysis and Risk Management for Biosimilars in Asia market

Track 2:Biosimilars- Hatch-Waxman Act & BPCI Act

• Track 2-1Regulatory prospects of BRIC countries

• Track 2-2Critical regulatory issues

• Track 2-3Recent Patent disputes and litigations

• Track 2-4Criteria for Patentability and Patent Claims

• Track 2-5Licensing of biosimilars

• Track 2-6BLA filing for biosimilars

• Track 2-7Biosimilars pricing regulation

Track 3:Challenges in Developing Biosimilars

• Track 3-1Equivalence of complex drug products

• Track 3-2Biosimilar monoclonal antibodies

• Track 3-3Economic aspect towards biosimilars

• Track 3-4Comparability for Biologics

• Track 3-5Advertising and promotion essentials

• Track 3-6Drug Safety essentials

• Track 3-7Late clinical development essentials

• Track 3-8Early clinical development essentials

• Track 3-9Unique considerations for biologics

• Track 3-10Current concepts of drugs and biologics

• Track 3-11Bioanalytical Challenges

• Track 3-12Consideration of biowaiver extensions for BCS class III drugs

Track 4:Biosimilars Research Pipeline

• Track 4-1Biotechnology medicinal products for different diseases/disorders

• Track 4-2Biosimilars for Autoimmune diseases

• Track 4-3Biosimilars in Dermatological diseases

• Track 4-4Biosimilar antibodies

• Track 4-5Biopharmaceuticals development

Track 5:Current Developments in The Field of Biosimilars

• Track 5-1Interchangeability of biosimilars

• Track 5-2Improvements in uptake of biosimilars

• Track 5-3Efficacy of biosimilars

• Track 5-4Evolution of Biosimilars in Developed and Developing Countries

• Track 5-5Scaling up considerations

• Track 5-6Improving Biosimilar process capabilities

Track 6:Pharmacovigilance of Biosimilars

• Track 6-1Current problems in pharmacovigilance

• Track 6-2Role of pharma industries in the improvement of pharmacovigilance system

• Track 6-3Detection and evaluation of drug safety signals

• Track 6-4Adverse drug reactions with pharmaceutical products

• Track 6-5Good pharmacovigilance practice and pharmacoepidemiology

Track 7:Emerging Trends in Biosimilars

• Track 7-1Biosimilars in Stem Cell Technology

• Track 7-2Improving characterization of biosimilars with technology

• Track 7-3Capacity for economic supremacy

Track 8:Biosimilars Market- Challenges & Prospects

• Track 8-1Proving the ROI (Return On Investment) of marketing activities

• Track 8-2QBD (Quality By Design)

• Track 8-3Long Term Sustainability & PLC (Product Life Cycle)

• Track 8-4Future of next generation biosimilars

• Track 8-5SWOT Analysis of Biosimilars

• Track 8-6Challenging potential & Competing Vs Generics

• Track 8-7Investment sources and venture capitals

Track 9:Cost Analysis of Biosimilars

• Track 9-1Pharmacoeconomic Modelling of Biosimilars

• Track 9-2Risk management plan (RMP) for Biosimilars

• Track 9-3Cost minimal analysis

• Track 9-4Cost benefit analysis

• Track 9-5Cost effectiveness analysis

• Track 9-6Cost utility analysis

• Track 9-7Quality adjusted life years

Track 10:Globalization of Biosimilars

• Track 10-1Global uptake of Biosimilars

• Track 10-2Global impact of biosimilars over generics

• Track 10-3Biosimilars in global market

• Track 10-4Investment and returns on biosimilars

• Track 10-5Cost and risk management

• Track 10-6Adopting innovative mechanisms such as risk-sharing arrangement

• Track 10-7Global P&R models for the biosimilars and generics market

Track 11:Biosimilars Analytical Strategies

• Track 11-1Biosimilar Bioanalytical methods

• Track 11-2Biosimilar Formulation

• Track 11-3Bioassay for comparability and potency testing

• Track 11-4Biosimilar GMP protein analysis

• Track 11-5Biosimilar LC/MS analysis for discovery, preclinical, and clinical programs

• Track 11-6Biosimilar Electrophoresis

• Track 11-7Biosimilar Multimodal techniques

Track 12:Emerging Biosimilars in Therapeutics

• Track 12-1Cancer therapeutics

• Track 12-2Recombinant vaccines

• Track 12-3Growth hormones

• Track 12-4Insulin Biosimilars

• Track 12-5Biosimilar peptides

• Track 12-6Recombinant therapeutic proteins

• Track 12-7Recombinant blood products

• Track 12-8Biosimilars in Fertility Treatment

• Track 12-9Biosimilar TNF-α

• Track 12-10Biosimilar Epoetins

• Track 12-11Biosimilar Interleukins

• Track 12-12Biosimilars in rheumatology

Track 13:Clinical Studies on Biosimilars

• Track 13-1Extrapolation of Indications in Biosimilars

• Track 13-2Biosimilars Clinical Studies

• Track 13-3Clinical trials on major diseases

• Track 13-4Risk management, and quality affairs

• Track 13-5Case studies, and clinical models

• Track 13-6Transgenic animals

• Track 13-7Targeted cell line development

• Track 13-8Clinical PK/PD studies

• Track 13-9Toxicological studies

• Track 13-10Biosimilars Clinical Trials

• Track 13-11Aspects of genotoxicity tests

Track 14:BCS & IVIVC Based Biowaivers

• Track 14-1BCS biowaivers

• Track 14-2Preclinical and clinical testing for oral drug delivery

• Track 14-3Waiver for In vivo bioavailability or bioequivalence

• Track 14-4In vitro diffusion cells for dissolution testing in formulation development

• Track 14-5Dissolution testing in drug formulation

• Track 14-6In vitro preclinical ADME/BCS testing

• Track 14-7In vitro drug product research

Track 15:Entrepreneurs Investment Meet